查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2094519

mRNA平台市場－2026-2032年全球市場預測

mRNA Platform Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，mRNA 平台市場將成長至 1,244.9 億美元，複合年成長率為 12.06%。

主要市場統計數據
基準年 2025 560.8億美元
預計年份：2026年 626.7億美元
預測年份 2032 1244.9億美元
複合年成長率 (%) 12.06%

mRNA平台已從專門的調查方法發展成為疫苗、腫瘤、罕見疾病、蛋白質替代療法和個人化醫療等領域的策略性生物製藥技術。其核心價值在於利用合成傳訊RNA（mRNA）引導細胞生產特定的抗原或治療性蛋白質，並依托核苷酸化學、脂質奈米顆粒遞送、純化、分析和可擴展生產等方面的進步。新冠疫情期間mRNA疫苗的成功應用展現了該平台的速度、模組化和適應性，同時也凸顯了低溫運輸穩定性、品管、監管協調、藥物安全監測和公眾信任的重要性。目前，mRNA平台的發展趨勢受到以下因素的影響：不斷拓展的治療產品線、改進的遞送系統、自擴增RNA（saRNA）技術、環狀RNA（circRNA）研究、組織靶向製劑以及對分散式生產能力的投入增加。產業相關人員日益關注提高熱穩定性、降低反應原性、拓展非感染疾病以及將數位技術整合到藥物發現和開發中。對於生物製藥、合約開發和生產、原料供應、臨床研究和公共衛生領域的相關人員，mRNA 平台代表著一個極具影響力的技術領域，其中科學差異化、生產基礎設施建設、監管合規性和公平獲取對於長期競爭力至關重要。

重塑mRNA平台的變革性變化。

隨著mRNA技術從應對疫情轉向更廣泛的治療和預防用途，其平台格局正在經歷一場變革性的轉變。其中一個關鍵轉變是從傳統的非複製型mRNA向新一代構建體（例如自擴增RNA和環狀RNA）的過渡，這些構建體有望提高蛋白質表達水平、降低劑量並增強免疫反應的持久性。另一個重大變革發生在遞送科學領域。雖然脂質奈米顆粒仍然是臨床驗證最充分的mRNA遞送系統，但對器官選擇性奈米顆粒、聚合物載體、肽基遞送和配體靶向製劑的研究正在加速推進，以提高組織特異性和安全性。在生產方面，疫苗生產正從緊急規模轉向靈活的、基於品質源於設計（QbD）的生產網路，這種網路能夠支持個人化癌症疫苗、多價感染疾病疫苗和小批量罕見疾病治療藥物的生產。監管要求也日趨複雜，更加重視RNA完整性、包封效率、功效測試、免疫抗原性、殘留雜質以及製程變更後的等效性等特性。同時，供應鏈也不斷成熟，尤其是在酵素、核苷酸、封端試劑、離子化脂質、一次性系統、無菌耗材和分析測試等領域。這些變化正推動mRNA平台走向更產業化，臨床應用日益多元化，並日益依賴生物學、化學、資料科學和先進製造技術等跨學科的綜合能力。

人工智慧對mRNA創新的累積影響

人工智慧 (AI) 正累積成為整個 mRNA 平台價值鏈的驅動力，從標靶選擇到生產製造，都能顯著提升速度、準確性和決策水平。在藥物發現階段，AI 驅動的序列設計支持密碼子最佳化、非翻譯區選擇、二級結構預測、抗原設計以及最大限度減少不必要的先天免疫活化。機器學習模型正被擴大應用於預測 RNA 穩定性、翻譯效率和分解模式，幫助研究人員設計表現更優的構建體。在遞送系統開發中，AI 可以透過關聯脂質化學性質、粒徑、電荷、包封率、生物分佈和生物反應，加速脂質奈米顆粒製劑的篩檢。在臨床開發中，AI 支持患者分層、生物標記發現、臨床實驗反應分析、標靶最佳化和真實世界安全性監測。 AI 在生產製造領域的應用也在不斷擴展，包括製程監控、偏差檢測、預測性維護、數位化批次記錄以及對關鍵品質屬性（例如 RNA 純度、殘留雙鏈RNA、效力和奈米顆粒一致性）的高級分析。 AI 不會取代核心科學檢驗；相反，其影響將是累積的，它將縮短實驗週期，提高篩選出有前景的候選物質的機率，並加強品管系統。隨著資料集標準化的推進和隱私保護型合作研究的改進，人工智慧有望在提高mRNA平台開發的可重複性、擴充性和快速應對新出現的健康威脅的能力方面發揮更大的作用。

全球mRNA平台生態系統的關鍵區域洞察

北美憑藉其成熟的生物醫學研究基礎設施、先進的臨床試驗網路、完善的先進生技藥品監管路徑以及強大的公私合營，仍然是mRNA平台開發領域最具影響力的地區之一。美國在mRNA疫苗檢驗、生產規模化、緊急應變框架和監管先例方面做出了重大貢獻，而加拿大則正在加強其國內生物製造能力和應對疫情的準備工作。歐洲的主要經濟體擁有強大的轉化研究能力、跨監管機構的合作以及完善的生物製造基礎，其中歐盟重點關注衛生安全、疫苗自主供應、藥物安全監測和先進療法的監管。英國、德國、法國、義大利和西班牙正透過臨床研究網路、學術生物技術叢集、精準醫療計畫以及對建構韌性醫療供應鏈的政策承諾，支持mRNA技術的進步。

影響mRNA平台採用的關鍵群體洞察

隨著東協成員國推動疫苗生產、參與臨床試驗、加強監管合作以及強化衛生安全規劃，東協在mRNA平台發展中扮演日益重要的角色。該地區應對感染疾病疫情的經驗促使其對高度適應性強的疫苗技術產生需求，而對生技藥品生產和區域供應鏈的投資則有助於提升應對力。海灣合作理事會（GCC）將生物技術定位為更廣泛的醫療衛生轉型的一部分，重點關注能夠支持本地生產、基因組學、精準醫療以及mRNA等先進療法的策略夥伴關係。歐盟在監管協調、藥物安全監測、跨境臨床研究、聯合緊急準備機制以及協調一致的突發公共衛生事件規劃方面發揮核心作用，是mRNA疫苗和療法的關鍵政策和創新平台。

主要國家mRNA平台開發趨勢

美國憑藉其強大的生物醫學研究能力、先進的監管經驗、大規模的臨床開發基礎設施和成熟的生物製造能力，在mRNA平台創新領域處於主導地位。加拿大正透過投資國內疫苗生產、學術研究和國家緊急準備來鞏固其地位。墨西哥憑藉其臨床研究能力、接近性北美供應鏈的優勢以及對生技藥品製造日益成長的興趣，正在提升其在該地區的重要性。巴西是拉丁美洲mRNA發展雄心的核心，這得益於其公共衛生基礎設施、疫苗生產記錄以及龐大的人口基數，後者需要可擴展的免疫策略。英國憑藉其強大的學術研究、臨床試驗能力、基因組學專業知識和以創新為導向的生命科學政策環境，正在支持mRNA領域的發展。德國是歐洲領先的mRNA科學、製造技術和先進療法開發中心，而法國則透過整合疫苗研究、監管專業知識和公共衛生基礎設施，支持該平台的演進。俄羅斯在免疫學和疫苗開發方面擁有科學實力，但國際合作和供應鏈趨勢正在影響其平台的發展。義大利和西班牙透過臨床研究網路、生物製藥生產以及參與歐洲健康舉措做出貢獻。

為mRNA平台領導者提供的實用建議

產業領導企業應優先考慮平台穩健性而非單一產品執行，投資於可重複使用的定序工具、檢驗的遞送系統、可擴展的生產流程和標準化的分析方法。加強在脂質奈米顆粒、RNA化學能力和功效檢測開發方面的專業知識對於提高產品品質和獲得監管機構的信任至關重要。各組織應為關鍵原料（例如核苷酸、酵素、封端試劑、可電離脂質、無菌過濾系統和一次性生物製程材料）建立穩健的供應鏈。為了實現臨床差異化，領導者應將業務領域從感染疾病疫苗擴展到腫瘤學、罕見疾病、自體免疫疾病、蛋白質替代療法和個人化免疫療法，同時保持嚴格的安全性和持久性證據標準。人工智慧應整合到藥物發現、製劑開發、臨床營運和生產分析中，但所有人工智慧驅動的決策都必須可追溯、檢驗並符合監管要求。此外，企業和公共部門相關人員應投資於耐熱製劑、區域生產能力、人力資源發展和技術轉移模式，以提高可及性和應對能力。與監管機構的合作應儘早啟動，尤其是在新型RNA形式、新型遞送系統和個人化產品方面。最後，領導者應加強與公眾的溝通，並宣傳mRNA的安全性、好處和局限性，因為其持續應用不僅取決於科學進步，還取決於透明度、藥物安全監測和信任。

調查方法

本執行摘要採用系統性的二手研究途徑編寫，重點在於與mRNA平台科學、開發、監管和商業化準備相關的、檢驗且有數據支持的資訊來源。該調查方法包括對公開的科學文獻、同行評審的研究、監管指南、公共衛生機構公告、臨床試驗註冊資訊、政府生物技術舉措、疫苗製備項目以及RNA生產、脂質奈米顆粒遞送、品管和藥物安全監測等技術資訊的審查和整合。區域、群體和國家層面的洞察來自已記錄的醫療保健基礎設施、生物製造能力、法規環境、公共衛生策略、臨床研究活動和研究生態系統指標。本分析不涉及市場估算、市場規模計算、市場佔有率評估和預測；而是著重於對技術趨勢、政策方向、與臨床開發的相關性以及營運影響進行定性和循證的解讀。資訊來源均經過可靠性、時效性、科學性和與mRNA平台價值鏈的相關性評估。由此得出的見解旨在為經營團隊在研究策略、生產準備、監管合規計劃、供應鏈韌性和區域優先事項等方面的決策提供支援。

結論：mRNA平台策略展望

mRNA平台已成為現代生物醫學的基礎技術，在快速疫苗研發中展現出重要性，並在腫瘤學、罕見疾病、蛋白質替代療法和精準醫療等領域展現出巨大潛力。其未來發展取決於RNA設計、遞送特異性、生產品質、熱穩定性、安全性監測和監管協調等方面的持續改進。人工智慧(AI)正在加速平台最佳化，而區域和地緣政治優先事項正在重塑各國和經濟體應對衛生安全、技術轉移和本地生物製造的方式。北美和歐洲繼續展現出強大的監管和創新領導力，而亞太地區正在迅速擴大生產和臨床能力。拉丁美洲、中東和非洲則日益關注可近性、準備工作和在地化。對於產業領導者而言，成功需要對平台科學、檢驗的分析方法、穩健的供應鏈、透明的溝通以及將創新與公平獲取相結合的合作模式進行規劃性投資。隨著 mRNA 平台日趨成熟，能夠主導的組織將是那些擁有傑出的科學能力、生產靈活性、監管遠見、嚴格的品管以及對公共健康做出明確貢獻的組織。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 mRNA平台市場：依產品類型分類

  • 診斷
    • 癌症
    • 感染疾病
  • 藥物發現試劑
    • 篩檢試劑
    • 轉染試劑
  • 調查工具包
    • 脂質奈米顆粒
    • mRNA合成試劑盒
  • 治療
    • 循環系統
    • 神經系統
    • 腫瘤學
    • 罕見疾病
  • 疫苗
    • 預防醫學
    • 治療藥物

第8章 mRNA平台市場：依治療領域分類

  • 循環系統
    • 心律不整
    • 心臟衰竭
  • 感染疾病
    • COVID-19
    • 流感
  • 神經系統
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固體癌
  • 罕見疾病
    • 遺傳性疾病
    • 代謝性疾病

第9章 mRNA平台市場：依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 皮下
  • 皮內給藥
  • 吸入
  • 鼻內

第10章 mRNA平台市場：依最終用戶分類

  • 學術機構
  • 診斷實驗室
  • 醫院
  • 製藥公司
  • 研究機構

第11章 mRNA平台市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第12章 mRNA平台市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第13章 mRNA平台市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Arcturus Therapeutics Holdings, Inc.
  • AstraZeneca PLC
  • BioNTech SE
  • Creative Biolabs
  • Croyez Bioscience Co., Ltd.
  • CureVac SE
  • Danaher Corporation
  • FUJIFILM Holdings Corporation
  • GENEWIZ Germany GmbH by Azenta Life Sciences
  • GenScript Biotech Corporation
  • GlaxoSmithKline plc
  • Gritstone bio, Inc.
  • Lonza Group AG
  • Merck KGaA
  • Moderna, Inc.
  • New England Biolabs, Inc.
  • Pfizer Inc.
  • Promega Corporation
  • Providence Therapeutics Holdings Inc.
  • Samsung Biologics Co., Ltd.
  • Sanofi SA
  • Sartorius AG
  • System Biosciences, LLC
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Vaxart, Inc.
Product Code: MRR-374DB5A05ED7

The mRNA Platform Market is projected to grow by USD 124.49 billion at a CAGR of 12.06% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 56.08 billion
Estimated Year [2026] USD 62.67 billion
Forecast Year [2032] USD 124.49 billion
CAGR (%) 12.06%

The mRNA platform has evolved from a specialized research modality into a strategic biopharmaceutical technology for vaccines, oncology, rare diseases, protein replacement, and personalized therapeutics. Its core value lies in using synthetic messenger RNA to instruct cells to produce specific antigens or therapeutic proteins, supported by advances in nucleotide chemistry, lipid nanoparticle delivery, purification, analytics, and scalable manufacturing. The success of mRNA-based vaccines during the COVID-19 pandemic validated the platform's speed, modularity, and adaptability, while also exposing the importance of cold-chain resilience, quality control, regulatory harmonization, pharmacovigilance, and public trust. Today, the mRNA platform landscape is shaped by expanding therapeutic pipelines, improved delivery systems, self-amplifying RNA approaches, circular RNA research, tissue-targeted formulations, and growing investment in distributed manufacturing capabilities. Industry participants are increasingly focused on improving thermostability, reducing reactogenicity, expanding indications beyond infectious diseases, and integrating digital technologies into discovery and development. For stakeholders across biopharma, contract development and manufacturing, raw material supply, clinical research, and public health, mRNA platforms represent a high-impact technology area where scientific differentiation, manufacturing readiness, regulatory execution, and equitable access define long-term competitiveness.

Transformative Shifts Reshaping mRNA Platforms

The mRNA platform landscape is undergoing transformative shifts as the technology moves from pandemic-response applications toward broader therapeutic and prophylactic use. One major shift is the transition from conventional non-replicating mRNA to next-generation constructs, including self-amplifying RNA and circular RNA, designed to improve protein expression, reduce dose requirements, and potentially enhance durability of response. Another critical transformation is occurring in delivery science. Lipid nanoparticles remain the most clinically validated delivery system for mRNA, but research is accelerating around organ-selective nanoparticles, polymer-based carriers, peptide-based delivery, and ligand-targeted formulations to improve tissue specificity and safety. Manufacturing is also shifting from emergency-scale vaccine production to flexible, quality-by-design production networks capable of supporting personalized cancer vaccines, multivalent infectious disease vaccines, and small-batch rare disease therapies. Regulatory expectations are becoming more sophisticated, with greater emphasis on characterization of RNA integrity, encapsulation efficiency, potency assays, immunogenicity, residual impurities, and comparability after process changes. At the same time, the supply chain is maturing, particularly for enzymes, nucleotides, capping reagents, ionizable lipids, single-use systems, sterile consumables, and analytical testing. These shifts are making the mRNA platform more industrialized, more clinically diverse, and more dependent on integrated capabilities across biology, chemistry, data science, and advanced manufacturing.

Cumulative Impact of Artificial Intelligence on mRNA Innovation

Artificial intelligence is becoming a cumulative force across the mRNA platform value chain, improving speed, precision, and decision-making from target selection through manufacturing. In discovery, AI-enabled sequence design supports codon optimization, untranslated region selection, secondary structure prediction, antigen design, and minimization of unwanted innate immune activation. Machine learning models are increasingly applied to predict RNA stability, translation efficiency, and degradation patterns, helping researchers design constructs with improved performance. In delivery development, AI can accelerate lipid nanoparticle formulation screening by linking lipid chemistry, particle size, charge, encapsulation efficiency, biodistribution, and biological response. In clinical development, AI supports patient stratification, biomarker discovery, immune-response analysis, trial-site optimization, and real-world safety surveillance. Manufacturing applications are also expanding, including process monitoring, deviation detection, predictive maintenance, digital batch records, and advanced analytics for critical quality attributes such as RNA purity, residual double-stranded RNA, potency, and nanoparticle consistency. The impact is cumulative because AI does not replace core scientific validation; rather, it compresses experimental cycles, improves the probability of selecting viable candidates, and strengthens quality systems. As datasets become more standardized and privacy-preserving collaboration improves, AI is expected to play a larger role in making mRNA platform development more reproducible, scalable, and responsive to emerging health threats.

Key Regional Insights Across the Global mRNA Platform Ecosystem

North America remains one of the most influential regions for mRNA platform development due to mature biomedical research infrastructure, advanced clinical trial networks, established regulatory pathways for advanced biologics, and strong public-private preparedness programs. The United States has contributed significantly to mRNA vaccine validation, manufacturing scale-up, emergency response frameworks, and regulatory precedent, while Canada has strengthened domestic biomanufacturing and pandemic preparedness capacity. Europe is defined by strong translational research, regulatory coordination, and biomanufacturing depth across major economies, with the European Union emphasizing health security, vaccine autonomy, pharmacovigilance, and advanced therapy oversight. The United Kingdom, Germany, France, Italy, and Spain support mRNA progress through clinical research networks, academic biotechnology clusters, precision medicine programs, and policy attention to resilient medical supply chains.

Asia-Pacific is rapidly advancing as China, India, Japan, South Korea, Australia, and ASEAN economies expand vaccine manufacturing, clinical research capabilities, and nucleic acid technology programs. The region's large population base, infectious disease burden, and growing innovation ecosystems support applications in vaccines and therapeutics, although regulatory alignment, cold-chain infrastructure, quality consistency, and technology transfer remain key priorities. Latin America is gaining relevance through vaccine access initiatives, regional manufacturing partnerships, and public health demand for rapid-response platforms, with Brazil and Mexico serving as important anchors for clinical research, immunization infrastructure, and biomanufacturing expansion. The Middle East is investing in biotechnology localization, health security, genomics, and precision medicine, particularly through Gulf economies seeking advanced manufacturing and research partnerships. Africa's mRNA platform trajectory is closely linked to vaccine equity, local manufacturing capacity, workforce training, and technology transfer, with regional initiatives focused on reducing dependence on imported vaccines and strengthening outbreak preparedness. Across all regions, the strategic direction is moving toward resilient mRNA manufacturing, regulatory readiness, workforce development, supply-chain security, and platform adaptability for both endemic and emerging diseases.

Key Group Insights Influencing mRNA Platform Adoption

ASEAN is increasingly relevant to the mRNA platform landscape because member economies are strengthening vaccine production, clinical trial participation, regulatory cooperation, and health security planning. The region's experience with infectious disease outbreaks supports demand for adaptable vaccine technologies, while investment in biologics manufacturing and regional supply chains can improve responsiveness to future public health needs. The GCC is positioning biotechnology as part of broader healthcare transformation, with emphasis on local manufacturing, genomics, precision medicine, and strategic partnerships that can support advanced modalities such as mRNA. The European Union plays a central role in regulatory convergence, pharmacovigilance, cross-border clinical research, joint preparedness mechanisms, and coordinated health emergency planning, making it a major policy and innovation bloc for mRNA vaccines and therapeutics.

BRICS countries are important because they combine large patient populations, expanding scientific capacity, public health manufacturing priorities, and growing interest in technology localization; China, India, Brazil, Russia, and South Africa each contribute different strengths in clinical scale, vaccine production, research infrastructure, immunization systems, or regional access. The G7 remains influential through advanced research funding, regulatory science, pandemic preparedness initiatives, and high-standard manufacturing ecosystems that shape global quality expectations for mRNA products. NATO countries, while not a healthcare bloc, are relevant through biosecurity, medical readiness, supply-chain resilience, and civil preparedness agendas that increasingly recognize vaccine platforms and rapid-response biomanufacturing as critical infrastructure. Together, these groupings influence the mRNA platform ecosystem through funding priorities, regulatory alignment, health security strategies, technology transfer, workforce development, and geopolitical emphasis on reliable access to vaccines and advanced therapeutics.

Key Country Insights for mRNA Platform Development

The United States is a leading country in mRNA platform innovation due to deep biomedical research capacity, advanced regulatory experience, large-scale clinical development infrastructure, and established biomanufacturing capabilities. Canada is strengthening its position through investments in domestic vaccine production, academic research, and national preparedness. Mexico contributes regional relevance through clinical research capabilities, proximity to North American supply chains, and increasing attention to biologics manufacturing. Brazil is central to Latin America's mRNA ambitions because of its public health infrastructure, vaccine production history, and large population requiring scalable immunization strategies. The United Kingdom supports mRNA progress through strong academic research, clinical trial capacity, genomics expertise, and an innovation-oriented life sciences policy environment. Germany is a major European hub for mRNA science, manufacturing know-how, and advanced therapeutic development, while France combines vaccine research, regulatory expertise, and public health infrastructure to support platform evolution. Russia has scientific capacity in immunology and vaccine development, although international collaboration and supply-chain dynamics affect its platform trajectory. Italy and Spain contribute through clinical research networks, biopharmaceutical manufacturing, and participation in European health initiatives.

China is advancing rapidly with extensive R&D activity, domestic vaccine manufacturing, and growing clinical evaluation of mRNA-based products across infectious disease and therapeutic areas. India is important for global vaccine production, cost-efficient manufacturing, clinical scale, and policy focus on biotechnology self-reliance, making it a key country for future mRNA access and localization. Japan brings strengths in precision medicine, regulatory rigor, advanced materials, and high-quality clinical research, supporting next-generation mRNA applications. Australia contributes through vaccine research, infectious disease surveillance, clinical trial infrastructure, and regional health partnerships. South Korea is emerging as a strategic mRNA manufacturing and innovation hub, supported by biologics production expertise, government-backed vaccine initiatives, and advanced healthcare infrastructure. Across these countries, the most important differentiators are regulatory maturity, lipid nanoparticle and RNA manufacturing capability, clinical trial readiness, talent availability, public health procurement strategy, pharmacovigilance systems, and the ability to convert platform science into safe, reproducible, and accessible products.

Actionable Recommendations for mRNA Platform Leaders

Industry leaders should prioritize platform robustness over single-product execution by investing in reusable sequence design tools, validated delivery systems, scalable manufacturing processes, and standardized analytical methods. Strengthening lipid nanoparticle expertise, RNA chemistry capabilities, and potency assay development is essential for improving product quality and regulatory confidence. Organizations should build resilient supply chains for critical inputs such as nucleotides, enzymes, capping reagents, ionizable lipids, sterile filtration systems, and single-use bioprocessing materials. To support clinical differentiation, leaders should expand beyond infectious disease vaccines into oncology, rare diseases, autoimmune disorders, protein replacement, and personalized immunotherapies while maintaining strong evidence standards for safety and durability. AI should be embedded into discovery, formulation, clinical operations, and manufacturing analytics, but all AI-driven decisions must remain traceable, validated, and aligned with regulatory expectations. Companies and public-sector stakeholders should also invest in thermostable formulations, regional manufacturing capacity, workforce training, and technology transfer models to improve access and preparedness. Regulatory engagement should begin early, especially for novel RNA formats, new delivery systems, and personalized products. Finally, leaders should improve public communication around mRNA safety, benefits, and limitations, because durable adoption depends not only on scientific progress but also on transparency, pharmacovigilance, and trust.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources relevant to mRNA platform science, development, regulation, and commercialization readiness. The methodology includes review and synthesis of publicly available scientific literature, peer-reviewed studies, regulatory guidance, public health agency communications, clinical trial registries, government biotechnology initiatives, vaccine preparedness programs, and technical information on RNA manufacturing, lipid nanoparticle delivery, quality control, and pharmacovigilance. Regional, group, and country insights are derived from documented healthcare infrastructure, biomanufacturing capabilities, regulatory environments, public health strategies, clinical research activity, and research ecosystem indicators. The analysis excludes market estimation, market sizing, market share assessment, and forecasting, and instead focuses on qualitative and evidence-based interpretation of technology trends, policy direction, clinical development relevance, and operational implications. Sources are assessed for credibility, recency, scientific consistency, and relevance to the mRNA platform value chain. The resulting insights are organized to support executive decision-making across research strategy, manufacturing readiness, regulatory planning, supply-chain resilience, and regional prioritization.

Conclusion: Strategic Outlook for the mRNA Platform

The mRNA platform is now a foundational technology in modern biomedicine, with proven relevance in rapid vaccine development and expanding potential across oncology, rare disease, protein replacement, and precision therapeutics. Its future trajectory depends on continued improvements in RNA design, delivery specificity, manufacturing quality, thermostability, safety monitoring, and regulatory harmonization. Artificial intelligence is accelerating platform optimization, while regional and geopolitical priorities are reshaping how countries and economic blocs approach health security, technology transfer, and local biomanufacturing. North America and Europe continue to provide strong regulatory and innovation leadership, Asia-Pacific is rapidly expanding manufacturing and clinical capabilities, and Latin America, the Middle East, and Africa are increasingly focused on access, preparedness, and localization. For industry leaders, success will require disciplined investment in platform science, validated analytics, resilient supply chains, transparent communication, and collaborative models that connect innovation with equitable access. As the mRNA platform matures, the organizations best positioned to lead will be those that combine scientific excellence with manufacturing agility, regulatory foresight, quality discipline, and a clear commitment to public health impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. mRNA Platform Market, by Product Type

  • 7.1. Introduction
  • 7.2. Diagnostics
    • 7.2.1. Cancer
    • 7.2.2. Infectious
  • 7.3. Drug Discovery Reagents
    • 7.3.1. Screening Reagents
    • 7.3.2. Transfection Reagents
  • 7.4. Research Kits
    • 7.4.1. Lipid Nanoparticles
    • 7.4.2. mRNA Synthesis Kits
  • 7.5. Therapeutics
    • 7.5.1. Cardiology
    • 7.5.2. Neurologic
    • 7.5.3. Oncology
    • 7.5.4. Rare Diseases
  • 7.6. Vaccines
    • 7.6.1. Prophylactic
    • 7.6.2. Therapeutic

8. mRNA Platform Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiology
    • 8.2.1. Arrhythmia
    • 8.2.2. Heart Failure
  • 8.3. Infectious
    • 8.3.1. COVID-19
    • 8.3.2. Influenza
  • 8.4. Neurologic
    • 8.4.1. Alzheimer's
    • 8.4.2. Parkinson's
  • 8.5. Oncology
    • 8.5.1. Hematologic Malignancies
    • 8.5.2. Solid Tumors
  • 8.6. Rare Diseases
    • 8.6.1. Genetic Disorders
    • 8.6.2. Metabolic Disorders

9. mRNA Platform Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intramuscular
  • 9.3. Intravenous
  • 9.4. Subcutaneous
  • 9.5. Intradermal
  • 9.6. Inhalation
  • 9.7. Intranasal

10. mRNA Platform Market, by End User

  • 10.1. Introduction
  • 10.2. Academic Centers
  • 10.3. Diagnostic Labs
  • 10.4. Hospitals
  • 10.5. Pharmaceutical Companies
  • 10.6. Research Institutes

11. mRNA Platform Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. Europe
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Africa
  • 11.6. Middle East

12. mRNA Platform Market, by Group

  • 12.1. NATO
  • 12.2. G7
  • 12.3. BRICS
  • 12.4. European Union
  • 12.5. ASEAN
  • 12.6. GCC

13. mRNA Platform Market, by Country

  • 13.1. China
  • 13.2. United States
  • 13.3. Japan
  • 13.4. India
  • 13.5. Germany
  • 13.6. United Kingdom
  • 13.7. Australia
  • 13.8. France
  • 13.9. South Korea
  • 13.10. Italy
  • 13.11. Canada
  • 13.12. Russia
  • 13.13. Brazil
  • 13.14. Mexico
  • 13.15. Spain

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Arcturus Therapeutics Holdings, Inc.
  • 15.2. AstraZeneca PLC
  • 15.3. BioNTech SE
  • 15.4. Creative Biolabs
  • 15.5. Croyez Bioscience Co., Ltd.
  • 15.6. CureVac SE
  • 15.7. Danaher Corporation
  • 15.8. FUJIFILM Holdings Corporation
  • 15.9. GENEWIZ Germany GmbH by Azenta Life Sciences
  • 15.10. GenScript Biotech Corporation
  • 15.11. GlaxoSmithKline plc
  • 15.12. Gritstone bio, Inc.
  • 15.13. Lonza Group AG
  • 15.14. Merck KGaA
  • 15.15. Moderna, Inc.
  • 15.16. New England Biolabs, Inc.
  • 15.17. Pfizer Inc.
  • 15.18. Promega Corporation
  • 15.19. Providence Therapeutics Holdings Inc.
  • 15.20. Samsung Biologics Co., Ltd.
  • 15.21. Sanofi S.A.
  • 15.22. Sartorius AG
  • 15.23. System Biosciences, LLC
  • 15.24. Takara Bio Inc.
  • 15.25. Thermo Fisher Scientific Inc.
  • 15.26. Vaxart, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRNA PLATFORM MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MRNA PLATFORM MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MRNA PLATFORM MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MRNA PLATFORM MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MRNA PLATFORM MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MRNA PLATFORM MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MRNA PLATFORM MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MRNA PLATFORM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MRNA PLATFORM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL MRNA PLATFORM MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL MRNA PLATFORM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL MRNA PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG DISCOVERY REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG DISCOVERY REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG DISCOVERY REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SCREENING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SCREENING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SCREENING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSFECTION REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSFECTION REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSFECTION REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RESEARCH KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESEARCH KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RESEARCH KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MRNA SYNTHESIS KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRNA SYNTHESIS KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MRNA SYNTHESIS KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROLOGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROLOGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROLOGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROPHYLACTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PROPHYLACTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROPHYLACTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CARDIOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CARDIOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARRHYTHMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARRHYTHMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARRHYTHMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COVID-19 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COVID-19 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COVID-19 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROLOGIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROLOGIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROLOGIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ALZHEIMER'S MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ALZHEIMER'S MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ALZHEIMER'S MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PARKINSON'S MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PARKINSON'S MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PARKINSON'S MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RARE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RARE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RARE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENETIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENETIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INTRANASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INTRANASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INTRANASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ACADEMIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ACADEMIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ACADEMIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL DIAGNOSTIC LABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL DIAGNOSTIC LABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL DIAGNOSTIC LABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL MRNA PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. NATO MRNA PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. NATO MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. NATO MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. NATO MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 232. NATO MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 233. NATO MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 234. NATO MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 235. NATO MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 236. NATO MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. NATO MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 239. NATO MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. G7 MRNA PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. G7 MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 251. G7 MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 254. G7 MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 256. G7 MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. G7 MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS MRNA PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN MRNA PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 303. GCC MRNA PLATFORM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 304. GCC MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. GCC MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 306. GCC MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 307. GCC MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 308. GCC MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 309. GCC MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 310. GCC MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 311. GCC MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 312. GCC MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 313. GCC MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 314. GCC MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. GCC MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 316. GCC MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. GCC MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. GLOBAL MRNA PLATFORM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA MRNA PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES MRNA PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED STATES MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED STATES MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 342. UNITED STATES MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 343. UNITED STATES MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 344. UNITED STATES MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 345. UNITED STATES MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 346. UNITED STATES MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 347. UNITED STATES MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 348. UNITED STATES MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 349. JAPAN MRNA PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 350. JAPAN MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. JAPAN MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 352. JAPAN MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 353. JAPAN MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 354. JAPAN MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 355. JAPAN MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 356. JAPAN MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 357. JAPAN MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 358. JAPAN MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 359. JAPAN MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 360. JAPAN MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 361. JAPAN MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 362. JAPAN MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 363. JAPAN MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 364. INDIA MRNA PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 365. INDIA MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 366. INDIA MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 367. INDIA MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 368. INDIA MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 369. INDIA MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 370. INDIA MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 371. INDIA MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 372. INDIA MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 373. INDIA MRNA PLATFORM MARKET SIZE, BY INFECTIOUS, 2018-2032 (USD MILLION)
  • TABLE 374. INDIA MRNA PLATFORM MARKET SIZE, BY NEUROLOGIC, 2018-2032 (USD MILLION)
  • TABLE 375. INDIA MRNA PLATFORM MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 376. INDIA MRNA PLATFORM MARKET SIZE, BY RARE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 377. INDIA MRNA PLATFORM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 378. INDIA MRNA PLATFORM MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 379. GERMANY MRNA PLATFORM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 380. GERMANY MRNA PLATFORM MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 381. GERMANY MRNA PLATFORM MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 382. GERMANY MRNA PLATFORM MARKET SIZE, BY DRUG DISCOVERY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 383. GERMANY MRNA PLATFORM MARKET SIZE, BY RESEARCH KITS, 2018-2032 (USD MILLION)
  • TABLE 384. GERMANY MRNA PLATFORM MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 385. GERMANY MRNA PLATFORM MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 386. GERMANY MRNA PLATFORM MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 387. GERMANY MRNA PLATFORM MARKET SIZE, BY CARDIOLOGY, 2018-2032 (USD MILLION)
  • TABLE 388. GERMANY MRNA